Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GENVEC ADDING THREE GENE THERAPY VECTOR APPROACHES VIA THERAGEN

Executive Summary

GENVEC ADDING THREE GENE THERAPY VECTOR APPROACHES VIA THERAGEN merger announced April 20. GenVec will be "in the unique position among gene therapy companies in its ability to screen and test gene product candidates in all four of the most widely used and studied vector systems," the company said. GenVec has been developing therapies based on in vivo delivery of adenovirus, while Theragen has been emphasizing research using the herpes simplex virus. Theragen also has conducted research with adeno- associated virus and liposomes.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS024371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel